TransCode TherapeuticsRNAZ
About: TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
Employees: 7
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
0.47% less ownership
Funds ownership: 1.88% [Q3] → 1.42% (-0.47%) [Q4]
56% less funds holding
Funds holding: 9 [Q3] → 4 (-5) [Q4]
82% less capital invested
Capital invested by funds: $186K [Q3] → $33.4K (-$152K) [Q4]
83% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 6
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Emily Bodnar 14% 1-year accuracy 23 / 160 met price target | 3,085%upside $10 | Buy Maintained | 16 Apr 2025 |
Financial journalist opinion
Based on 4 articles about RNAZ published over the past 30 days









